Dunhill Financial’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.66K Buy
226
+220
+3,667% +$46.7K ﹤0.01% 965
2026
Q2
$1.43K Sell
6
-1
-14% -$191 ﹤0.01% 940
2026
Q1
$1.34K Buy
7
+2
+40% +$369 ﹤0.01% 901
2025
Q4
$893 Buy
5
+2
+67% +$327 ﹤0.01% 849
2025
Q3
$422 Sell
3
-1
-25% -$135 ﹤0.01% 868
2025
Q2
$627 Sell
4
-6
-60% -$748 ﹤0.01% 832
2025
Q1
$1.39K Sell
10
-142
-93% -$20.3K ﹤0.01% 786
2024
Q4
$23.3K Buy
152
+50
+49% +$8.43K 0.01% 262
2024
Q3
$19.8K Buy
102
+15
+17% +$3.14K 0.01% 278
2024
Q2
$20.1K Buy
87
+76
+691% +$16.5K 0.01% 212
2024
Q1
$2.31K Sell
11
-12
-52% -$2.81K ﹤0.01% 466
2023
Q4
$5.94K Buy
+23
New +$5.65K 0.01% 274

Other funds holding BIIB

Dunhill Financial's BIIB Position: Q3 2026 in Review

Dunhill Financial increased its Biogen (BIIB) stake by 3,667% in Q3 2026, buying an estimated $46.7K and bringing the position to 226 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Dunhill Financial first reported a position in BIIB in Q4 2023 and has held it in 12 quarters since. The position peaked at $23.3K in Q4 2024. 1,059 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Dunhill Financial held 226 shares of Biogen worth $1.66K as of Q3 2026.
  • Dunhill Financial bought 220 Biogen shares in Q3 2026, an estimated $46.7K.
  • Biogen made up ﹤0.01% of Dunhill Financial's portfolio in Q3 2026, its #965 holding.
  • Dunhill Financial first reported a position in Biogen in Q4 2023 and has held it in 12 quarters since.
  • Dunhill Financial's Biogen position peaked at $23.3K in Q4 2024.
  • 1,059 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Dunhill Financial's 13F filing for Q3 2026, filed 16 Nov 2026.